AR076748A1 - Formulaciones estables de anticuerpos anti-tnf-alfa humanos con grandes concentraciones de proteinas. metodo de tratamiento - Google Patents
Formulaciones estables de anticuerpos anti-tnf-alfa humanos con grandes concentraciones de proteinas. metodo de tratamientoInfo
- Publication number
- AR076748A1 AR076748A1 ARP100101510A ARP100101510A AR076748A1 AR 076748 A1 AR076748 A1 AR 076748A1 AR P100101510 A ARP100101510 A AR P100101510A AR P100101510 A ARP100101510 A AR P100101510A AR 076748 A1 AR076748 A1 AR 076748A1
- Authority
- AR
- Argentina
- Prior art keywords
- approximately
- formulation
- seq
- amino acid
- acid sequence
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 10
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 9
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 8
- 238000006467 substitution reaction Methods 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 239000007788 liquid Substances 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 229920005862 polyol Polymers 0.000 abstract 3
- 150000003077 polyols Chemical class 0.000 abstract 3
- 235000004279 alanine Nutrition 0.000 abstract 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 2
- 230000004048 modification Effects 0.000 abstract 2
- 150000005846 sugar alcohols Chemical class 0.000 abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 2
- 229960002964 adalimumab Drugs 0.000 abstract 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 1
- 229910000397 disodium phosphate Inorganic materials 0.000 abstract 1
- 235000019800 disodium phosphate Nutrition 0.000 abstract 1
- 235000019799 monosodium phosphate Nutrition 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 229940068968 polysorbate 80 Drugs 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 abstract 1
- 229910000162 sodium phosphate Inorganic materials 0.000 abstract 1
- 238000003756 stirring Methods 0.000 abstract 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
Abstract
Reivindicacion 1: Una formulacion farmacéutica líquida, caracterizada porque comprende más de 20 mg aproximadamente de un poliol y al menos 100 mg/ml aproximadamente de un anticuerpo anti-TNF-alfa humano, o una porcion de union al antígeno del mismo, que comprende una cadena liviana que comprende un dominio CDR3 cuya secuencia de aminoácidos se muestra en la SEQ ID N°: 3, o una modificacion de la SEQ ID N°: 3 por una sola sustitucion de alanina en la posicion 1, 4, 5, 7 u 8 o por una a cinco sustituciones de aminoácidos conservadores en las posiciones 1, 3, 4, 6, 7, 8 y/o 9, y una cadena pesada que comprende un dominio CDR3 cuya secuencia de aminoácidos que se muestra en la SEQ ID N°: 4, o una modificacion de la SEQ ID N°: 4 por una sola sustitucion de alanina en la posicion 2, 3, 4, 5, 6, 8, 9, 10 u 11 o por una a cinco sustituciones de aminoácidos conservadores en las posiciones 2, 3, 4, 5, 6, 8, 9, 10, 11 y/o 12, en donde la formulacion no contiene al excipiente NaCI. Reivindicacion 4: La formulacion de la reivindicacion 1, caracterizada porque la formulacion comprende 40-45 mg aproximadamente del poliol. Reivindicacion 5: La formulacion de cualquiera de las reivindicaciones 1-4, caracterizada porque el poliol es un alcohol de azucar. Reivindicacion 10: La formulacion de cualquiera de las reivindicaciones 1-6, caracterizada porque el anticuerpo es adalimumab. Reivindicacion 11: Una formulacion farmacéutica líquida, caracterizada porque tiene un valor de pH de entre 5,0 y 6,4 aproximadamente y que comprende al menos 100 mg/ml aproximadamente de un anticuerpo anti-TNF-alfa humano, o una porcion de union al antígeno del mismo, que comprende una cadena liviana que comprende un dominio CDR3 que comprende una secuencia de aminoácidos que se muestra en la SEQ ID N°: 3 y una cadena pesada que comprende un dominio CDR3 que comprende una secuencia de aminoácidos que se muestra en la SEQ ID N°: 4, en donde la formulacion no contiene NaCI y tiene una turbidez menor que 60 NTU aproximadamente después de un ensayo estándar de estrés por agitacion de 24 horas. Reivindicacion 21: La formulacion de cualquiera de las reivindicaciones 11-20, caracterizada porque contiene menos que un 1% aproximadamente de proteína agregada. Reivindicacion 26: Una formulacion farmacéutica líquida, caracterizada porque comprende al menos 100 mg/ml aproximadamente de un anticuerpo anti-TNF-alfa humano, o una porcion de union al antígeno del mismo, que comprende una cadena liviana que comprende un dominio CDR3 que comprende una secuencia de aminoácidos que se muestra en la SEQ ID N°: 3 y una cadena pesada que comprende un dominio CDR3 que comprende una secuencia de aminoácidos que se muestra en la SEQ ID N°: 4; más de 20 mg aproximadamente/ml de un alcohol de azucar; 0,1-2,0 mg/ml aproximadamente de un agente tensioactivo; 1,15-1,45 mg/ml aproximadamente de ácido cítrico * H2O; 0,2-0,4 mg/ml aproximadamente de citrato de sodio deshidratado; 1,35-1,75 mg/ml aproximadamente de Na2HPO4 * 2 H2O; 0,75-0,95 mg/ml aproximadamente de NaH2PO4 * 2 H2O, en donde la formulacion tiene una valor de pH de entre 4,7 y 6,5 aproximadamente y no comprende NaCI. Reivindicacion 29. La formulacion de la reivindicacion 26, caracterizada porque el agente tensioactivo es Polysorbate 80.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17538009P | 2009-05-04 | 2009-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076748A1 true AR076748A1 (es) | 2011-07-06 |
Family
ID=43030509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101510A AR076748A1 (es) | 2009-05-04 | 2010-05-04 | Formulaciones estables de anticuerpos anti-tnf-alfa humanos con grandes concentraciones de proteinas. metodo de tratamiento |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20100278822A1 (es) |
| EP (1) | EP2427211A4 (es) |
| JP (1) | JP2012526121A (es) |
| KR (1) | KR20120038406A (es) |
| CN (2) | CN102458469B (es) |
| AR (1) | AR076748A1 (es) |
| AU (1) | AU2010246168A1 (es) |
| CA (1) | CA2760185A1 (es) |
| IL (1) | IL215643A0 (es) |
| MX (1) | MX2011011772A (es) |
| NZ (2) | NZ613809A (es) |
| RU (1) | RU2560701C2 (es) |
| SG (2) | SG175188A1 (es) |
| TW (2) | TW201526923A (es) |
| UY (1) | UY32609A (es) |
| WO (1) | WO2010129469A1 (es) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| CZ292465B6 (cs) | 1996-02-09 | 2003-09-17 | Abbott Laboratories (Bermuda) Ltd. | Lidské protilátky k lidskému TNFalfa |
| CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| PL218992B1 (pl) * | 2002-07-19 | 2015-02-27 | Abbott Biotech Ltd | Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ |
| US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| TWI556829B (zh) | 2004-04-09 | 2016-11-11 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
| US20060083741A1 (en) * | 2004-10-08 | 2006-04-20 | Hoffman Rebecca S | Treatment of respiratory syncytial virus (RSV) infection |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| CA2903138A1 (en) | 2005-05-16 | 2006-11-23 | Abbvie Biotechnology Ltd. | Use of tnfa inhibitor for treatment of erosive polyarthritis |
| AU2006337105B2 (en) | 2005-11-01 | 2013-05-02 | Abbvie Biotechnology Ltd | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
| EP2004689A4 (en) | 2006-04-05 | 2010-06-02 | Abbott Biotech Ltd | PURIFICATION OF ANTIBODIES |
| US9605064B2 (en) * | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| EP2007426A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS |
| US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
| EP2012586A4 (en) | 2006-04-10 | 2010-08-18 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS |
| WO2007120656A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of rheumatoid arthritis |
| US20080311043A1 (en) * | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| CN103316403B (zh) | 2006-06-30 | 2017-05-24 | 艾伯维生物技术有限公司 | 自动注射装置 |
| MX2009004351A (es) * | 2006-10-27 | 2009-05-12 | Abbott Biotech Ltd | Anticuerpos anti-htnfalfa cristalinos. |
| NZ580379A (en) | 2007-03-29 | 2012-10-26 | Abbott Lab | Crystalline anti-human il-12 antibodies |
| US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
| US20090110679A1 (en) * | 2007-07-13 | 2009-04-30 | Luk-Chiu Li | Methods and compositions for pulmonary administration of a TNFa inhibitor |
| SG183709A1 (en) | 2007-08-08 | 2012-09-27 | Abbott Lab | Compositions and methods for crystallizing antibodies |
| CA2707483A1 (en) * | 2007-11-30 | 2009-06-11 | Wolfgang Fraunhofer | Protein formulations and methods of making same |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| JP2011510267A (ja) * | 2008-01-03 | 2011-03-31 | アボツト・バイオテクノロジー・リミテツド | 乾癬の治療における化合物の長期的効力の予測 |
| KR20100120289A (ko) | 2008-01-15 | 2010-11-15 | 애보트 게엠베하 운트 콤파니 카게 | 분말상 단백질 조성물 및 이의 제조 방법 |
| TWI583418B (zh) | 2009-04-29 | 2017-05-21 | 艾伯維生物技術有限責任公司 | 針筒柱塞及自動注射裝置 |
| TWI584838B (zh) | 2009-12-15 | 2017-06-01 | 艾伯維生物技術有限責任公司 | 用於自動注射裝置之改良發射按鈕 |
| JP2013518590A (ja) | 2010-02-02 | 2013-05-23 | アボツト・バイオテクノロジー・リミテツド | ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物 |
| HUE039740T2 (hu) | 2010-06-03 | 2019-01-28 | Abbvie Biotechnology Ltd | Alkalmazások és készítmények hidradenitis suppurativa (HS) kezelésére |
| PL2637690T3 (pl) * | 2010-11-11 | 2017-03-31 | Abbvie Biotechnology Ltd | Płynne formulacje zawierające przeciwciało anty-tnf alfa o wysokim stężeniu |
| EP3187216B1 (en) | 2011-01-24 | 2019-08-21 | AbbVie Biotechnology Ltd. | Automatic injection devices having overmolded gripping surfaces |
| ES2734076T3 (es) * | 2011-02-17 | 2019-12-04 | Kyowa Hakko Kirin Co Ltd | Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| CN103501825B (zh) | 2011-05-02 | 2017-03-15 | 免疫医疗公司 | 用于小体积施用的同种异型选择的抗体的超滤浓缩 |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| WO2013096835A1 (en) * | 2011-12-23 | 2013-06-27 | Abbvie Inc. | Stable protein formulations |
| SG10201609982PA (en) | 2012-03-07 | 2017-01-27 | Cadila Healthcare Ltd | Pharmaceutical formulations of tnf-alpha anitbodies |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| WO2013186230A1 (en) * | 2012-06-12 | 2013-12-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation for a therapeutic antibody |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US9206390B2 (en) | 2012-09-02 | 2015-12-08 | Abbvie, Inc. | Methods to control protein heterogeneity |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| PE20150964A1 (es) | 2012-09-07 | 2015-07-25 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
| US10058589B2 (en) * | 2012-10-26 | 2018-08-28 | Lupin Limited | Stable pharmaceutical composition of Etanercept in a phosphate citrate buffer with glycine as an anti-aggregating agent |
| WO2014078627A1 (en) * | 2012-11-19 | 2014-05-22 | Merck Sharp & Dohme Corp. | Liquid formulations for tnfr:fc fusion proteins |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| WO2014099636A1 (en) * | 2012-12-18 | 2014-06-26 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-tnf alpha antibody |
| CN102988984B (zh) * | 2012-12-21 | 2015-05-20 | 嘉和生物药业有限公司 | 增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂 |
| KR20150110659A (ko) * | 2013-01-24 | 2015-10-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Tnf-알파 항원-결합 단백질 |
| SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
| UY35460A (es) * | 2013-03-15 | 2014-10-31 | Bayer Healthcare Llc | Formulaciones de anticuerpos anti-receptor de prolactina |
| CN103446583B (zh) * | 2013-03-21 | 2015-11-18 | 百奥泰生物科技(广州)有限公司 | 一种治疗TNF-α相关疾病的人抗体制剂 |
| JP2014202667A (ja) * | 2013-04-08 | 2014-10-27 | 株式会社島津製作所 | 抗体医薬用粒子径分布測定装置及び抗体医薬の粒子径分布測定方法 |
| US20160129112A1 (en) * | 2013-05-28 | 2016-05-12 | Momenta Pharmaceuticals, Inc. | Pharmaceutical Compositions Comprising Pyrophosphate |
| EP3021833B2 (en) * | 2013-07-19 | 2022-03-30 | Hexal Aktiengesellschaft | Methods and formulations which allow the modulation of immune responses related to the administration of a biopharmaceutical drug |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| AU2014337263B2 (en) * | 2013-10-16 | 2019-12-12 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| EP3892288A1 (en) * | 2013-10-24 | 2021-10-13 | Astrazeneca AB | Stable, aqueous antibody formulations |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| CN104666242B (zh) * | 2013-11-26 | 2018-01-02 | 信达生物制药(苏州)有限公司 | 一种稳定的抗TNF‑α抗体制剂及其用途 |
| BR112016011224A2 (pt) * | 2013-11-29 | 2017-09-19 | Ares Trading Sa | Formulação líquida de uma proteína de fusão que compreende tnfr e região de fc |
| CN104707146B (zh) * | 2013-12-16 | 2019-04-16 | 浙江海正药业股份有限公司 | 一种含有阿达木单抗的药物组合物 |
| CA2943919A1 (en) * | 2014-03-29 | 2015-10-08 | Intas Pharmaceuticals Ltd. | Lyophilized pharmaceutical composition of fc-peptide fusion protein |
| EP2946767B1 (en) * | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| HUE029849T2 (en) | 2014-05-23 | 2017-04-28 | Ares Trading Sa | Liquid pharmaceutical composition |
| CA2950577A1 (en) * | 2014-05-27 | 2015-12-03 | Academia Sinica | Fucosidase from bacteroides and methods using the same |
| EP3156071A4 (en) * | 2014-06-10 | 2018-01-10 | Meiji Seika Pharma Co., Ltd. | Stable aqueous adalimumab preparation |
| AR102198A1 (es) * | 2014-10-09 | 2017-02-08 | Regeneron Pharma | Proceso para reducir partículas subvisibles en una formulación farmacéutica |
| US10696735B2 (en) | 2015-01-21 | 2020-06-30 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| AR103544A1 (es) * | 2015-01-28 | 2017-05-17 | Mabxience S A | FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a |
| EP3053572A1 (en) * | 2015-02-06 | 2016-08-10 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3078675A1 (en) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| AU2016362129A1 (en) | 2015-12-04 | 2018-06-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| CN109563161A (zh) * | 2016-02-03 | 2019-04-02 | 安口生物公司 | 用于提高抗体稳定性的缓冲制剂 |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| SI3479819T1 (sl) | 2016-06-30 | 2024-06-28 | Celltrion Inc. | Stabilen tekoči farmacevtski pripravek |
| CN119119244A (zh) | 2016-08-16 | 2024-12-13 | 里珍纳龙药品有限公司 | 用于对混合物中的个体抗体进行量化的方法 |
| KR102564393B1 (ko) | 2016-10-25 | 2023-08-08 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피 데이터 분석을 위한 방법 및 시스템 |
| RU2665966C2 (ru) * | 2016-12-30 | 2018-09-05 | Закрытое Акционерное Общество "Биокад" | Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα |
| RU2764521C2 (ru) * | 2017-12-29 | 2022-01-18 | Закрытое Акционерное Общество "Биокад" | Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОа |
| US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
| EP3372241A1 (en) * | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3372242A1 (en) * | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| SG11201907434RA (en) | 2017-03-22 | 2019-10-30 | Novartis Ag | Compositions and methods for immunooncology |
| WO2018187074A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| MX2019013072A (es) | 2017-05-02 | 2019-12-16 | Merck Sharp & Dohme | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CN107485713B (zh) * | 2017-07-31 | 2018-08-28 | 百奥泰生物科技(广州)有限公司 | 针对TNF-α的抗体组合物及其应用 |
| KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
| IL272954B2 (en) | 2017-09-19 | 2024-06-01 | Regeneron Pharma | Methods of reducing particle formation and compositions formed thereby |
| WO2019057631A1 (en) | 2017-09-20 | 2019-03-28 | Alvotech Hf | PHARMACEUTICAL FORMULATIONS FOR ADALIMUMAB |
| EA202090802A1 (ru) | 2017-09-30 | 2020-08-05 | Биоселз (Бейдзин) Биотек Ко., Лтд. | Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью |
| CN112004827A (zh) * | 2018-03-23 | 2020-11-27 | 艾伯维德国有限责任两合公司 | 稳定的水性抗tau抗体调配物 |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| AU2019377456A1 (en) | 2018-11-07 | 2021-05-27 | Merck Sharp & Dohme Llc | Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| EP3941521A1 (en) * | 2019-03-18 | 2022-01-26 | Alvotech HF | Aqueous formulations of tnf-alpha antibodies in high concentrations |
| US20230158143A1 (en) * | 2020-05-21 | 2023-05-25 | Shilpa Medicare Ltd | Pharmaceutical compositions comprising adalimumab |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5237054A (en) * | 1987-02-20 | 1993-08-17 | Akzo Pharma | Stabilized aqueous composition containing antibodies |
| US5945098A (en) * | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| GB9122820D0 (en) * | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| ZA955642B (en) * | 1994-07-07 | 1997-05-06 | Ortho Pharma Corp | Lyophilized imaging agent formulation |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| CZ292465B6 (cs) * | 1996-02-09 | 2003-09-17 | Abbott Laboratories (Bermuda) Ltd. | Lidské protilátky k lidskému TNFalfa |
| GB9610992D0 (en) * | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| SE9803710L (sv) * | 1998-09-25 | 2000-03-26 | A & Science Invest Ab | Användning av vissa substanser för behandling av nervrotsskador |
| CA2371427A1 (en) * | 1999-04-28 | 2000-11-09 | Yamanouchi Pharmaceutical Co., Ltd. | Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof |
| DE10022092A1 (de) * | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| WO2002011753A1 (en) * | 2000-08-04 | 2002-02-14 | Chugai Seiyaku Kabushiki Kaisha | Protein injection preparations |
| UA81743C2 (uk) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| SE0003045D0 (sv) * | 2000-08-29 | 2000-08-29 | Probi Ab | New method |
| WO2002030463A2 (en) * | 2000-10-12 | 2002-04-18 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| WO2002096461A1 (en) * | 2001-05-25 | 2002-12-05 | Abbott Gmbh & Co. Kg | Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients |
| JP5052736B2 (ja) * | 2001-05-30 | 2012-10-17 | 中外製薬株式会社 | タンパク質製剤 |
| IL159048A0 (en) * | 2001-06-21 | 2004-05-12 | Genentech Inc | Sustained release formulation |
| WO2003009817A2 (en) * | 2001-07-25 | 2003-02-06 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| CN1292655C (zh) * | 2001-11-08 | 2007-01-03 | 蛋白质设计实验室股份有限公司 | IgG抗体稳定的液态药物制剂 |
| EP1585477A4 (en) * | 2001-11-30 | 2007-06-27 | Centocor Inc | ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES |
| GB0202633D0 (en) * | 2002-02-05 | 2002-03-20 | Delta Biotechnology Ltd | Stabilization of protein preparations |
| AU2003211991B2 (en) * | 2002-02-14 | 2008-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing solution formulations |
| US20030161828A1 (en) * | 2002-02-19 | 2003-08-28 | Abbott Gmbh & Co. Kg | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure |
| US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| CN1671741A (zh) * | 2002-06-21 | 2005-09-21 | 拜奥根Idec公司 | 浓缩抗体的缓冲剂制剂及其使用方法 |
| PL218992B1 (pl) * | 2002-07-19 | 2015-02-27 | Abbott Biotech Ltd | Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| EP1592440A4 (en) * | 2003-02-10 | 2007-07-11 | Elan Pharm Inc | IMMUNOGLOBULIN PREPARATION AND METHOD OF PRODUCING THE SAME |
| US8937045B2 (en) * | 2003-02-28 | 2015-01-20 | Ares Trading S.A. | Liquid formulations of tumor necrosis factor-binding proteins |
| JP4607010B2 (ja) * | 2003-02-28 | 2011-01-05 | 中外製薬株式会社 | タンパク質含有安定化製剤 |
| CA2519408C (en) * | 2003-04-04 | 2011-01-18 | Genentech, Inc. | High concentration antibody and protein formulations |
| FR2853551B1 (fr) * | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee |
| CN100522998C (zh) * | 2003-10-01 | 2009-08-05 | 协和发酵麒麟株式会社 | 抗体的稳定化方法和被稳定的溶液状抗体制剂 |
| DE10355251A1 (de) * | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
| EP1712240B1 (en) * | 2003-12-25 | 2015-09-09 | Kyowa Hakko Kirin Co., Ltd. | Stable water-based medicinal preparation containing antibody |
| EP1722819B1 (en) * | 2004-03-12 | 2007-12-26 | Intercell AG | Method for solubilising peptide mixtures |
| US7279448B2 (en) * | 2004-07-08 | 2007-10-09 | The United States Of America, As Represented By The Secretary Of Agriculture | Poly(hydroxy thioether) vegetable oil derivatives useful as lubricant additives |
| TW200621282A (en) * | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| US7119876B2 (en) * | 2004-10-18 | 2006-10-10 | Asml Netherlands B.V. | Lithographic apparatus and device manufacturing method |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| TWI398272B (zh) * | 2005-03-08 | 2013-06-11 | Intervet Int Bv | 化學定義的安定劑 |
| CN101166763B (zh) * | 2005-04-18 | 2012-09-19 | 伊达研究和发展有限公司 | 稳定的抗乙肝病毒(hbv)抗体配制剂 |
| CA2903138A1 (en) * | 2005-05-16 | 2006-11-23 | Abbvie Biotechnology Ltd. | Use of tnfa inhibitor for treatment of erosive polyarthritis |
| EP2264162A1 (en) * | 2005-07-02 | 2010-12-22 | Arecor Limited | Stable aqueous systems comprising proteins |
| EP1909838A2 (en) * | 2005-07-29 | 2008-04-16 | Amgen Inc. | Formulations that inhibit protein aggregation |
| BRPI0614100A2 (pt) * | 2005-08-03 | 2011-03-09 | Immunogen Inc | formulações de imunoconjugado lìquidas |
| WO2007037795A2 (en) * | 2005-08-05 | 2007-04-05 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
| US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| AU2006337105B2 (en) * | 2005-11-01 | 2013-05-02 | Abbvie Biotechnology Ltd | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
| JP5405122B2 (ja) * | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
| KR20080098504A (ko) * | 2006-02-03 | 2008-11-10 | 메디뮨 엘엘씨 | 단백질 제제 |
| JP5364382B2 (ja) * | 2006-02-07 | 2013-12-11 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 遊離チオール部分を有するタンパク質の安定化された組成物 |
| EP2004689A4 (en) * | 2006-04-05 | 2010-06-02 | Abbott Biotech Ltd | PURIFICATION OF ANTIBODIES |
| US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| US9605064B2 (en) * | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| EP2012586A4 (en) * | 2006-04-10 | 2010-08-18 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS |
| WO2007120656A2 (en) * | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of rheumatoid arthritis |
| US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| JP2009534390A (ja) * | 2006-04-21 | 2009-09-24 | アムジェン インコーポレイテッド | 生物医薬品製剤のための緩衝剤 |
| US20100021451A1 (en) * | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| CN103316403B (zh) * | 2006-06-30 | 2017-05-24 | 艾伯维生物技术有限公司 | 自动注射装置 |
| AU2007300221A1 (en) * | 2006-09-25 | 2008-04-03 | Medimmune, Llc. | Stabilized antibody formulations and uses thereof |
| EP2081553B1 (en) * | 2006-10-06 | 2020-08-12 | Amgen Inc. | Stable antibody formulations |
| WO2008051363A2 (en) * | 2006-10-20 | 2008-05-02 | Amgen Inc. | Stable polypeptide formulations |
| MX2009004351A (es) * | 2006-10-27 | 2009-05-12 | Abbott Biotech Ltd | Anticuerpos anti-htnfalfa cristalinos. |
| CA2671571A1 (en) * | 2006-12-06 | 2008-06-12 | Wyeth | High protein concentration formulations containing mannitol |
| GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| CA2683317C (en) * | 2007-04-26 | 2014-12-16 | Bayer Healthcare Llc | Stabilization of liquid solutions of recombinant protein for frozen storage |
| EP2679996A1 (en) * | 2007-05-31 | 2014-01-01 | AbbVie Inc. | Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders |
| MX2009012964A (es) * | 2007-06-01 | 2010-01-14 | Acologix Inc | Formulacion de peptido estable a alta temperatura. |
| EP2152318A4 (en) * | 2007-06-01 | 2011-12-07 | Abbott Biotech Ltd | COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE |
| US20110014676A1 (en) * | 2007-06-29 | 2011-01-20 | Battelle Memorial Institute | Protein stabilization |
| US20090110679A1 (en) * | 2007-07-13 | 2009-04-30 | Luk-Chiu Li | Methods and compositions for pulmonary administration of a TNFa inhibitor |
| US20090029794A1 (en) * | 2007-07-23 | 2009-01-29 | Yung-Hsiung Chen | Golf Club Head that Reduces a Contact Resistance with the Ground |
| SG183709A1 (en) * | 2007-08-08 | 2012-09-27 | Abbott Lab | Compositions and methods for crystallizing antibodies |
| MX2010010503A (es) * | 2008-03-24 | 2010-11-09 | Abbott Biotech Ltd | Metodos y composiciones para tratar perdida osea. |
| TWI583418B (zh) * | 2009-04-29 | 2017-05-21 | 艾伯維生物技術有限責任公司 | 針筒柱塞及自動注射裝置 |
| JP2013518590A (ja) * | 2010-02-02 | 2013-05-23 | アボツト・バイオテクノロジー・リミテツド | ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物 |
-
2010
- 2010-05-03 NZ NZ613809A patent/NZ613809A/en not_active IP Right Cessation
- 2010-05-03 RU RU2011149327/15A patent/RU2560701C2/ru not_active IP Right Cessation
- 2010-05-03 NZ NZ595694A patent/NZ595694A/xx not_active IP Right Cessation
- 2010-05-03 CA CA2760185A patent/CA2760185A1/en not_active Abandoned
- 2010-05-03 MX MX2011011772A patent/MX2011011772A/es not_active Application Discontinuation
- 2010-05-03 EP EP10772644.0A patent/EP2427211A4/en not_active Withdrawn
- 2010-05-03 US US12/772,595 patent/US20100278822A1/en not_active Abandoned
- 2010-05-03 SG SG2011074341A patent/SG175188A1/en unknown
- 2010-05-03 JP JP2012509873A patent/JP2012526121A/ja active Pending
- 2010-05-03 KR KR1020117029006A patent/KR20120038406A/ko not_active Withdrawn
- 2010-05-03 AU AU2010246168A patent/AU2010246168A1/en not_active Abandoned
- 2010-05-03 WO PCT/US2010/033387 patent/WO2010129469A1/en not_active Ceased
- 2010-05-03 SG SG10201401995UA patent/SG10201401995UA/en unknown
- 2010-05-03 CN CN201080030083.9A patent/CN102458469B/zh not_active Expired - Fee Related
- 2010-05-03 CN CN201410669393.5A patent/CN104490767A/zh active Pending
- 2010-05-04 TW TW104107818A patent/TW201526923A/zh unknown
- 2010-05-04 UY UY0001032609A patent/UY32609A/es not_active Application Discontinuation
- 2010-05-04 AR ARP100101510A patent/AR076748A1/es unknown
- 2010-05-04 TW TW099114238A patent/TWI480064B/zh not_active IP Right Cessation
-
2011
- 2011-10-09 IL IL215643A patent/IL215643A0/en unknown
-
2014
- 2014-01-31 US US14/170,026 patent/US20140141007A1/en not_active Abandoned
- 2014-01-31 US US14/170,061 patent/US20140141008A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN102458469A (zh) | 2012-05-16 |
| US20140141008A1 (en) | 2014-05-22 |
| RU2011149327A (ru) | 2013-06-10 |
| CN104490767A (zh) | 2015-04-08 |
| US20140141007A1 (en) | 2014-05-22 |
| US20100278822A1 (en) | 2010-11-04 |
| KR20120038406A (ko) | 2012-04-23 |
| AU2010246168A1 (en) | 2011-11-10 |
| IL215643A0 (en) | 2012-01-31 |
| SG175188A1 (en) | 2011-11-28 |
| NZ595694A (en) | 2013-09-27 |
| CN102458469B (zh) | 2014-12-24 |
| UY32609A (es) | 2010-12-31 |
| WO2010129469A1 (en) | 2010-11-11 |
| CA2760185A1 (en) | 2010-11-11 |
| JP2012526121A (ja) | 2012-10-25 |
| SG10201401995UA (en) | 2014-08-28 |
| MX2011011772A (es) | 2012-02-08 |
| EP2427211A4 (en) | 2013-05-01 |
| RU2560701C2 (ru) | 2015-08-20 |
| WO2010129469A8 (en) | 2012-02-23 |
| TW201043263A (en) | 2010-12-16 |
| TW201526923A (zh) | 2015-07-16 |
| TWI480064B (zh) | 2015-04-11 |
| NZ613809A (en) | 2015-02-27 |
| EP2427211A1 (en) | 2012-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076748A1 (es) | Formulaciones estables de anticuerpos anti-tnf-alfa humanos con grandes concentraciones de proteinas. metodo de tratamiento | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| JP2012526121A5 (es) | ||
| AR082257A1 (es) | Composicion de inmunoglobulinas humanas concentradas, procedimiento | |
| AR092216A1 (es) | Formulaciones estables de anticuerpos contra tslp | |
| ES2531083T3 (es) | Formulaciones estables de polipéptidos y usos de las mismas | |
| ECSP099642A (es) | Formulaciones estables de anticuerpo | |
| AR067011A1 (es) | Formulaciones de anticuerpos | |
| HRP20160362T1 (hr) | Antigeni pripravak protiv bakterija iz roda mycobacterium | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| FI3408295T3 (fi) | Bispesifisiä vasta-ainekonstrukteja käsittävä farmaseuttinen koostumus | |
| EP4233892A3 (en) | Stable anti-ifnar1 formulation | |
| NZ627859A (en) | Stabilized formulations containing anti-ang2 antibodies | |
| JP2008515775A5 (es) | ||
| RU2011142184A (ru) | Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами | |
| RU2015123476A (ru) | Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения | |
| MX2015015152A (es) | Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13. | |
| TNSN08511A1 (en) | Lyophilized formulations of anti-egfr antibodies | |
| NZ630885A (en) | Antibody formulation | |
| EA201992570A1 (ru) | Составы на основе человеческих антител к rankl, а также способы их применения | |
| AR084627A1 (es) | Formulacion farmaceutica que comprende una droga biofarmaceutica | |
| ATE344803T1 (de) | Schimärische amyloid-beta peptide | |
| PE20061043A1 (es) | Composicion farmaceutica que comprende anticuerpos monoclonales | |
| PE20120170A1 (es) | Variantes de union a anti-albumina de suero mejoradas | |
| MX2016003705A (es) | Formulacion de un conjugado de hormona del crecimiento humana de accion prolongada. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |